Skip to main content
Clinical Trials/CTRI/2012/12/003195
CTRI/2012/12/003195
Recruiting
Phase 4

An, observational study to evaluate the efficacy and safety of daptomycin in suspected or culture proven gram positive bacteremia in adults with End Stage Renal Disease on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis

ovartis Healthcare Pvt Ltd0 sites50 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- gram positive bacteremia
Sponsor
ovartis Healthcare Pvt Ltd
Enrollment
50
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Sponsor
ovartis Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • Male or female greater than 18 years of age;
  • Suspected or Culture proven gram positive bacteremia. Note â?? patients with mixed infections (i.e. with anaerobic or gram negative bacteremia in addition) may be included.
  • End\-stage renal disease (ESRD) patients on stable dialysis regimen
  • Written informed consent prior to any study\-related procedure not part of normal medical care;
  • Considered to be in appropriate health for study entry by the Investigator (e.g., no acute, debilitating medical problems) and appropriate candidate for completing study treatment;
  • If female of childbearing potential; willing to practice reliable birth control measures during study treatment, not lactating or pregnant, has a documented negative pregnancy test result within 24 hours prior to study medication administration, and willing to practice effective means of birth control for greater than 28 days after study completion;
  • If infected catheter lines or devices (if any) are removed but patient continuing on daptomycin therapy data will still be collected. Removal of lines or devices will be at the discretion of the investigator as clinical indicated.

Exclusion Criteria

  • Females: if pregnant or lactating;
  • Received an investigational drug (including experimental biologic agents) within 30 days of study entry;
  • Suspected or known concomitant infection which may interfere with the study outcome.
  • Known to be allergic or intolerant to daptomycin;
  • Patients with evidence of resistance to daptomycin
  • Patients with only Gram negative bacteremia.
  • Patients diagnosed with Peritonitis.
  • Baseline creatinine phosphokinase (CPK) values 3X ULN (upper limit of normal);
  • Known HIV\-infected subjects with CD4 count less than or equal to 200 cells per cubic mm;
  • Active illicit drug and/or alcohol abuse;

Outcomes

Primary Outcomes

Not specified

Similar Trials